Drugs Containing Excipient (Inactive Ingredient) ANHYDROUS CITRIC ACID

« Back to Dashboard

Branded drugs containing ANHYDROUS CITRIC ACID excipient, and estimated key patent expiration / generic entry dates

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Merck Sharp & Dohme LLC	STROMECTOL	ivermectin	0006-0032	ANHYDROUS CITRIC ACID
Pharmacia & Upjohn Company LLC	ZYVOX	linezolid	0009-4992	ANHYDROUS CITRIC ACID
Pharmacia & Upjohn Company LLC	ZYVOX	linezolid	0009-5137	ANHYDROUS CITRIC ACID
Pharmacia & Upjohn Company LLC	ZYVOX	linezolid	0009-7807	ANHYDROUS CITRIC ACID

Generic drugs containing ANHYDROUS CITRIC ACID excipient

Company	Ingredient	NDC	Excipient
Eli Lilly and Company	dulaglutide	0002-1433	ANHYDROUS CITRIC ACID
Eli Lilly and Company	mirikizumab-mrkz	0002-7575	ANHYDROUS CITRIC ACID
Eli Lilly and Company	necitumumab	0002-7716	ANHYDROUS CITRIC ACID
Eli Lilly and Company	donanemab-azbt	0002-9401	ANHYDROUS CITRIC ACID

Anhydrous Citric Acid Pharmaceutical Excipient Market: Dynamics, Pricing, Supply Chain, and Financial Trajectory

Last updated: October 4, 2026

Anhydrous citric acid is a mature, low-cost pharmaceutical excipient with stable demand in effervescent tablets, oral powders, granules, liquid formulations, and pH-adjusted products. Its financial profile is driven less by intellectual property than by fermentation capacity, sugar and energy costs, China-linked supply, freight, quality compliance, and pharmaceutical-grade qualification.

The market has limited pricing power because the active chemical is commoditized and multiple manufacturers produce equivalent compendial grades. Premium pricing remains available for validated pharmaceutical supply, low-bioburden material, reliable documentation, regional inventory, and dual-source programs. Revenue growth is likely to track pharmaceutical dosage-volume growth rather than innovation-led price expansion.

Market factor	Current position
Chemical name	Citric acid, anhydrous
CAS number	77-92-9
Primary pharmaceutical role	Acidulant, pH adjuster, chelating agent, effervescent component
Main dosage forms	Tablets, powders, granules, oral liquids, reconstitution products
Manufacturing route	Microbial fermentation, followed by recovery, purification, crystallization, and drying
Core supply regions	China, Europe, North America, India, and Southeast Asia
Principal cost drivers	Carbohydrate feedstock, electricity, steam, labor, water treatment, freight, compliance
Patent position	No meaningful composition-of-matter exclusivity
Regulatory position	Established pharmacopeial excipient with broad pharmaceutical use
Commercial outlook	Stable volume growth, cyclical pricing, moderate margin pressure

What is anhydrous citric acid used for in pharmaceutical formulations?

Anhydrous citric acid is used where formulators need acidity without the water associated with the monohydrate form. Its principal applications include:

• Effervescent tablets and powders, usually combined with sodium bicarbonate or carbonate.
• Oral powders and granules.
• pH adjustment in oral solutions and suspensions.
• Chelation of trace metal ions that can catalyze oxidation.
• Taste modification in liquid and pediatric medicines.
• Buffer systems when combined with citrate salts.
• Processing aids in dry pharmaceutical blends.

The anhydrous grade is useful in moisture-sensitive products because it contributes less water to the formulation than citric acid monohydrate. That distinction matters in effervescent systems, where premature moisture uptake can trigger reaction between the acid and carbonate components.

Anhydrous citric acid is generally selected on the basis of assay, water content, particle-size distribution, residual solvents, elemental impurities, microbial quality, and consistency of dissolution. Grade selection can affect blend uniformity, tablet compression, effervescence rate, stability, and packaging requirements.

How is pharmaceutical-grade anhydrous citric acid manufactured?

Commercial anhydrous citric acid is produced mainly through fermentation of carbohydrate feedstocks, historically using Aspergillus niger or related industrial fermentation systems. The process usually includes:

1. Preparation of a sugar or carbohydrate substrate.
2. Controlled microbial fermentation.
3. Removal of biomass and impurities.
4. Recovery and purification of citric acid.
5. Crystallization.
6. Separation, drying, milling, and packaging.

The economics are closely linked to corn, glucose, sucrose, molasses, and other carbohydrate inputs. Electricity and steam are also material costs because fermentation, evaporation, drying, and water treatment require substantial utility consumption.

Manufacturing qualification is more demanding for pharmaceutical supply than for food or industrial citric acid. Drug-product customers typically require documented change control, validated analytical methods, traceability, audit rights, impurity controls, and compliance with current good manufacturing practice expectations.

Which companies manufacture pharmaceutical-grade anhydrous citric acid?

The global supply base includes large multinational ingredient suppliers and major Chinese fermentation producers. Relevant commercial participants include:

• Jungbunzlauer, a major producer of citric acid and pharmaceutical excipients.
• ADM, which supplies citric acid and other functional ingredients.
• Cargill, which participates in citric acid and formulation ingredient markets.
• RZBC Group, a significant Chinese citric acid producer.
• Weifang Ensign Industry, a large Chinese citric acid manufacturer.
• TTCA and other Chinese fermentation producers.
• Gadot Biochemical Industries, which supplies citric acid and related ingredients.
• Regional distributors and specialty excipient companies that qualify and stock pharmaceutical grades.

The supplier universe is broader than the list of companies selling directly to pharmaceutical manufacturers. Many suppliers sell through distributors, while some drug companies qualify a producer but purchase from a regional distributor for inventory, documentation, and logistics support.

What drives the anhydrous citric acid pharmaceutical excipient market?

The market is shaped by five main factors.

Pharmaceutical dosage-volume growth

Demand follows production of oral solid dosage forms, effervescent products, electrolyte products, vitamins, supplements, pediatric medicines, and generic formulations. Growth is strongest in emerging markets where oral formulations and consumer health products continue to expand.

Feedstock and energy economics

Citric acid production is fermentation-intensive. Higher sugar, corn, glucose, coal, natural gas, electricity, or steam costs compress producer margins unless contracts permit pass-through pricing. When feedstock costs decline, excess capacity can push prices lower.

Chinese production and export availability

China is a major global production center. Chinese capacity influences international pricing, freight flows, and availability in Europe, North America, India, and other importing regions. Export competition has historically limited global price increases, while plant outages, environmental controls, shipping disruptions, and trade restrictions can produce temporary tightening.

Pharmaceutical qualification

Drug manufacturers do not treat every citric acid supplier as interchangeable. A switch can require supplier qualification, analytical comparability, stability work, process validation, regulatory assessment, and sometimes customer notification. These barriers create customer retention even when the chemical itself is readily available.

Moisture and packaging requirements

Anhydrous citric acid remains sensitive to moisture. Packaging, warehouse conditions, shipping duration, and container integrity affect product performance. Pharmaceutical buyers may pay a premium for controlled packaging, low moisture, consistent particle size, and regional stock.

What is the financial trajectory for anhydrous citric acid?

Anhydrous citric acid is a volume-driven specialty commodity rather than a high-margin proprietary excipient. The likely financial trajectory has four characteristics:

Financial variable	Expected direction
Volume demand	Low- to mid-single-digit growth linked to oral dosage and consumer-health production
Average selling price	Cyclical, with pressure during oversupply and increases during feedstock or logistics shocks
Gross margin	Higher for validated pharmaceutical grades than for food or industrial grades
R&D intensity	Low at the molecule level; moderate for particle engineering, low-bioburden grades, and formulation systems
Working capital	Sensitive to inventory buffers, freight lead times, and customer qualification cycles
Consolidation pressure	Persistent because scale reduces fermentation and recovery costs

Public companies generally do not report pharmaceutical-grade anhydrous citric acid as a separate revenue line. Financial analysis therefore requires separating total citric acid revenue from pharmaceutical excipient sales. Published market reports also use inconsistent definitions, often combining food, beverage, pharmaceutical, detergent, and industrial applications. A pharmaceutical-only market estimate should not be derived from total citric acid sales without applying an explicit end-use allocation.

The strongest financial opportunity is not the basic molecule. It is the supply package around the molecule: compendial compliance, low endotoxin or low bioburden options, particle-size control, global regulatory support, shorter lead times, and reliable supply continuity.

How do pharmaceutical-grade and food-grade anhydrous citric acid compare?

Attribute	Pharmaceutical grade	Food grade
Primary standards	USP-NF, Ph. Eur., BP, JP where applicable	FCC and food regulations
Documentation	Extensive batch records, change control, audit support	Usually less extensive
Qualification	Formal excipient and supplier qualification	Food supplier approval
Impurity control	Tighter customer-specific requirements	Food-safety focused
Packaging	Controlled, often pharmaceutical-labeled	Bulk food packaging
Pricing	Usually higher	Usually lower
Switching cost	High after formulation qualification	Lower in many applications
Primary buyer	Drug manufacturer, CDMO, excipient distributor	Food, beverage, industrial buyer

A food-grade material cannot automatically substitute for pharmaceutical-grade material. The drug manufacturer must confirm compendial compliance, manufacturing controls, impurity profile, documentation, and suitability for the intended dosage form.

What regulatory standards apply to anhydrous citric acid?

Anhydrous citric acid is covered by major pharmaceutical compendia, including the United States Pharmacopeia-National Formulary and European Pharmacopoeia. Specific monograph requirements can include identification, assay, water, sulfated ash or residue on ignition, readily carbonizable substances, heavy metals or elemental impurities, and related quality tests.

In the United States, excipient use is supported by FDA’s Inactive Ingredient Database when the ingredient and route-specific use are listed. The database is a regulatory reference for prior use in approved drug products, but it does not eliminate the need for product-specific formulation, quality, and regulatory assessment. FDA also recognizes citric acid in food and pharmaceutical contexts under applicable regulations and guidance. [1][2]

Important compliance areas include:

• Current good manufacturing practice controls.
• IPEC-PQG excipient GMP principles.
• Elemental impurity risk assessment under ICH Q3D.
• Nitrosamine and mutagenic impurity assessments where relevant to the process.
• Microbial and bioburden controls.
• Supplier change notification.
• Pharmacopoeial testing and certificate-of-analysis integrity.

What patents protect anhydrous citric acid?

The citric acid molecule and ordinary anhydrous citric acid manufacturing process are not protected by meaningful, enforceable composition-of-matter patents. Citric acid is an established substance with a long industrial history.

Patent risk can arise around downstream formulations rather than the excipient itself. Relevant patent categories include:

• Effervescent tablet compositions.
• Moisture-protected granules.
• Controlled-release dosage forms containing citrate systems.
• Taste-masking systems.
• Specific particle-size distributions.
• Drying, coating, or agglomeration technologies.
• Combination products using citric acid with active pharmaceutical ingredients.
• Manufacturing processes with defined crystallization or purification conditions.

A pharmaceutical company using anhydrous citric acid generally faces formulation patent risk only when the finished dosage form falls within claims covering a specific composition, process, release profile, or therapeutic use.

What is the Orange Book status of anhydrous citric acid?

Anhydrous citric acid is not an independently approved active pharmaceutical ingredient with standalone Orange Book exclusivity. It is an inactive ingredient used within approved drug products. As a result:

• There is no standalone Orange Book listing for the excipient.
• There is no separate five-year new chemical entity exclusivity.
• There is no excipient-specific Paragraph IV pathway.
• Patents listed for a finished drug may cover the formulation, method of use, dosage form, or delivery system containing citric acid.
• Generic applicants assess the listed patents for the finished drug, not for citric acid as a raw material.

The FDA Orange Book remains relevant only when anhydrous citric acid is incorporated into a branded drug product with listed patents. [3]

When does anhydrous citric acid lose exclusivity?

Anhydrous citric acid has no meaningful current exclusivity period to lose. The chemical is off-patent and available from multiple qualified suppliers.

Exclusivity concerns arise at the finished-product level. A drug containing anhydrous citric acid may remain protected by:

• Formulation patents.
• Method-of-use patents.
• Device or delivery patents.
• Pediatric exclusivity.
• Orphan-drug exclusivity.
• Regulatory exclusivity associated with the active ingredient.

Those protections belong to the drug product and its sponsor, not to the excipient manufacturer.

What patent litigation and Paragraph IV risk affect citric acid products?

There is no broad patent litigation category focused on anhydrous citric acid as an excipient. Paragraph IV litigation can arise when a generic applicant challenges patents listed for a branded drug formulation that contains citric acid.

The main litigation questions are whether the generic product:

• Uses the same or an equivalent effervescent system.
• Falls within a claimed pH or buffer range.
• Uses a patented particle-size or granulation profile.
• Meets a claimed dissolution or release limitation.
• Practices a patented method of treatment.

Settlement agreements may delay generic entry while allowing an authorized generic, license, or date-certain launch. These agreements must be assessed at the finished-drug level and cannot be inferred from the absence of citric-acid patents.

What manufacturing and intellectual-property barriers matter most?

The strongest barriers are operational rather than patent-based.

Manufacturing barriers

• Scale-efficient fermentation.
• Reliable carbohydrate feedstock.
• High-yield microbial strains.
• Wastewater and biomass management.
• Crystallization and drying control.
• Low-moisture packaging.
• Compliance with customer audits.
• Regional inventory and continuity planning.

Intellectual-property barriers

• Proprietary fermentation strains.
• Process-control methods.
• Crystallization and particle engineering.
• Coated or granulated excipient systems.
• Finished-product formulation patents.

Trade secrets and manufacturing know-how are more important than public patent exclusivity for the base excipient.

How does anhydrous citric acid compare with citric acid monohydrate?

Attribute	Anhydrous citric acid	Citric acid monohydrate
Bound water	Essentially absent by designation	Contains crystallization water
Moisture-sensitive formulations	Often preferred	May require tighter moisture control
Effervescent systems	Commonly used	Also used, depending on formulation
Molecular weight basis	Lower than monohydrate	Higher because of water of crystallization
Dose calculation	Requires anhydrous-equivalent calculation	Requires monohydrate-equivalent calculation
Stability impact	Lower intrinsic water contribution	Higher water contribution
Cost	Can command a modest premium	Often broadly available
Substitution	Requires reformulation assessment	Not automatically interchangeable

The two forms are chemically related but not automatically interchangeable on a one-to-one mass basis. Water content affects stoichiometry, assay calculations, tablet weight, reaction kinetics, and stability.

What generic launch risks exist for drugs containing anhydrous citric acid?

The excipient itself creates little generic-entry risk because it is widely available. The principal risks are:

1. Finished-product formulation patents.
2. Difficulty reproducing effervescence, dissolution, taste, or stability.
3. Supplier qualification and change-control requirements.
4. Patent claims covering particle size, granulation, or moisture protection.
5. Manufacturing differences that affect bioequivalence or product performance.
6. Regulatory scrutiny of inactive-ingredient amounts and route-specific precedent.

Generic applicants can usually source anhydrous citric acid from multiple producers. The greater risk is demonstrating that the complete formulation is equivalent and does not infringe listed or unlisted patent claims.

What is the geographic coverage of the anhydrous citric acid supply chain?

The supply chain is global but concentrated in fermentation-capable regions.

• China provides substantial export capacity and often sets the marginal global price.
• Europe has strong pharmaceutical-grade production and regulatory support.
• North America has major ingredient distributors and qualified supply channels.
• India is a growing pharmaceutical manufacturing and excipient market.
• Southeast Asia is important as a manufacturing and consumption region.

Regional buyers increasingly seek dual sourcing, local inventory, and alternate manufacturing sites. Freight disruption, tariffs, export controls, environmental inspections, and currency movements can change delivered cost even when the factory price is stable.

Key Takeaways

• Anhydrous citric acid is a mature, off-patent pharmaceutical excipient.
• Demand is tied to oral dosage forms, effervescent products, consumer health, and generic medicines.
• Pricing is cyclical and depends heavily on sugar, energy, logistics, and Chinese export supply.
• Pharmaceutical-grade material earns a premium through documentation, qualification, low moisture, particle control, and supply reliability.
• No standalone Orange Book, Paragraph IV, or exclusivity issue applies to the excipient itself.
• Patent risk is concentrated in finished-product formulations, delivery systems, and methods of use.
• Manufacturing know-how, fermentation scale, quality systems, and regional inventory are stronger barriers than molecule-level intellectual property.
• Financial growth should be modeled through volume, price cycles, qualification retention, and premium-grade mix rather than patent-driven pricing.

FAQs

Is anhydrous citric acid considered an active pharmaceutical ingredient?

No. It is generally an inactive pharmaceutical ingredient, although it can have a functional role as an acidulant, buffer component, chelating agent, or effervescent reactant.

Can pharmaceutical manufacturers replace anhydrous citric acid with monohydrate?

Only after formulation and regulatory assessment. The forms differ in water content, molecular weight, stoichiometry, moisture contribution, and potentially dissolution or effervescence behavior.

Does China control the global citric acid pharmaceutical market?

China has major influence over global supply and pricing, but the pharmaceutical market also includes European, North American, Indian, and regional suppliers. Pharmaceutical buyers often maintain qualified alternatives because supply continuity is critical.

Is citric acid subject to pharmaceutical excipient patents?

The basic molecule and conventional anhydrous form are not meaningfully protected by current composition patents. Patents may cover specific formulations, granules, particle sizes, coatings, or finished drug products.

What creates the highest margin in citric acid excipients?

The highest margin generally comes from validated pharmaceutical grades, controlled particle-size products, low-bioburden or specialized grades, regional inventory, regulatory support, and formulation services rather than from commodity citric acid volume.

References

1. U.S. Food and Drug Administration. (n.d.). Inactive Ingredient Database. https://www.accessdata.fda.gov/scripts/cder/iig/index.cfm

2. U.S. Food and Drug Administration. (2023). Current good manufacturing practice, quality systems, and pharmaceutical excipients guidance and regulations. https://www.fda.gov

3. U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations: Orange Book. https://www.accessdata.fda.gov/scripts/cder/ob/index.cfm

4. United States Pharmacopeial Convention. (2024). United States Pharmacopeia and National Formulary: Citric acid monograph. U.S. Pharmacopeial Convention.

5. European Directorate for the Quality of Medicines & HealthCare. (2024). European Pharmacopoeia: Citric acid monograph. Council of Europe.

6. International Pharmaceutical Excipients Council. (2017). The joint IPEC-PQG good manufacturing practices guide for pharmaceutical excipients. IPEC Federation.

7. Grand View Research. (2024). Citric acid market size, share and trends analysis report. Grand View Research.